A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy

G. Palareti, C. Legnani, A. Lee, C. Manotti, J. Hirsh, A. D'Angelo, V. Pengo, M. Moia, S. Coccheri

Research output: Contribution to journalArticlepeer-review

Abstract

The optimal long-term treatment of acute venous thromboembolism (VTE) in patients with malignancy remains undefined. In particular, based on current e vidence, it is uncertain whether secondary prophylaxis using standard intensity oral anticoagulant therapy is associated with higher risks of bleeding and recurrent thrombosis in patients with cancer than in those without cancer. This study compared with outcome of anticoagulation corses in 95 patien ts with malignancy with those of 733 patients with malignancy. All patients were participants in a large, nation-wide population study and were prospe ctively followed from the initiation of their oral anticoagulation therapy. Based on 744 patient-years of treatment and follow-up, the rates of major (5.4% vs0.9%) minor (16.2% vs 3.6%) and total (21.6% vs 4.5%) bleeding were statistically significantly higher in cancer patients compared with patien ts without cancer. Bleeding was also a more frequent cause of early anticoagulation withdrawal in patients with malignancy (4.2% vs. 0.7%;

Original languageEnglish
Pages (from-to)805-810
Number of pages6
JournalThrombosis and Haemostasis
Volume84
Issue number5
Publication statusPublished - 2000

Keywords

  • Cancer
  • DVT
  • Oral anticoagulation
  • Safety

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy'. Together they form a unique fingerprint.

Cite this